.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
Argus Health
AstraZeneca
Deloitte
Novartis
Chubb
Daiichi Sankyo
Healthtrust
Merck

Generated: December 16, 2017

DrugPatentWatch Database Preview

LOVAZA Drug Profile

« Back to Dashboard

When do Lovaza patents expire, and what generic alternatives are available?

Lovaza is a drug marketed by Smithkline Beecham and is included in one NDA.

The generic ingredient in LOVAZA is omega-3-acid ethyl esters. There are thirteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the omega-3-acid ethyl esters profile page.
Drug patent expirations by year for LOVAZA

Pharmacology for LOVAZA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline BeechamLOVAZAomega-3-acid ethyl estersCAPSULE;ORAL021654-001Nov 10, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LOVAZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline BeechamLOVAZAomega-3-acid ethyl estersCAPSULE;ORAL021654-001Nov 10, 2004► Subscribe► Subscribe
Smithkline BeechamLOVAZAomega-3-acid ethyl estersCAPSULE;ORAL021654-001Nov 10, 2004► Subscribe► Subscribe
Smithkline BeechamLOVAZAomega-3-acid ethyl estersCAPSULE;ORAL021654-001Nov 10, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LOVAZA

Drugname Dosage Strength RLD Submissiondate
omega-3-acid ethyl estersCapsules1 gLovaza11/10/2008

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Dow
US Army
Fuji
Johnson and Johnson
UBS
Federal Trade Commission
Medtronic
Teva
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot